DAHUDER Medical Journal最新文献

{"title":"Dietary supplements and Side Effects: Persistent Atrial Fibrillation","authors":"O. Gokdemir, Aysegul KARAMAN ULUTAN","doi":"10.56016/dahudermj.1184388","DOIUrl":"https://doi.org/10.56016/dahudermj.1184388","url":null,"abstract":"Dietary supplements, also known as food or nutritional supplements, are intended to compensate for nutrient deficiencies or to maintain the proper nutrient balance in the diet. As dietary supplements are not permitted by law to be marketed as a treatment, prevention, or cure for any disease; only drugs are permitted to make such claims physicians should be aware of the fact that individuals using these supplements could affect their health. \u0000A 22-year-old man presented to the emergency department with palpitations and dyspnea of recent onset (>2 hours). His medical history revealed nothing noteworthy. His physical examination revealed tachyarrhythmia. His electrocardiography revealed an AF speed of 130 beats per minute (ECG). In this case, a young man who was using Jack3D and diagnosed with atrial fibrillation has been presented which has been unique. \u0000Despite the fact that natural products in food supplements are more expensive than synthetic ones, the majority of people prefer them. This could be because they believe natural products are more beneficial and safe for their health. As a result, this is a significant public health issue that also poses a financial risk.","PeriodicalId":210697,"journal":{"name":"DAHUDER Medical Journal","volume":"37 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116484014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of prognostic factors in febrile neutropenic patients with hematological malignancies","authors":"A. Gümüş, N. Erben, G. Usluer, E. Gunduz","doi":"10.56016/dahudermj.1187628","DOIUrl":"https://doi.org/10.56016/dahudermj.1187628","url":null,"abstract":"Objectives: Hematological malignancies presenting with febrile neutropenia constitute an important health issue all over the globe. In this study, we aimed to elucidate the prognostic factors of febrile neutropenic patients with hematological malignancies and to investigate the causes of mortality. \u0000Method: This research had a retrospective nature. A total of 174 febrile neutropenia patients ≥ 18 years of age hospitalized have been enrolled in the study. Patients enrolled in the analysis were determined according to the American Society for Infectious Diseases 2010 Febrile Neutropenia Diagnosis and Treatment Guidelines. Accordingly, neutropenia was defined as an expected decrease in the absolute neutrophil count (ANS) to < 500 cells/mm³ or < 500 cells/mm³ over the next 48 hours and body temperature over ≥ 38°C. \u0000Results: A total of 174 patients have been included in the analysis and 32 (18.5%) died while 142 (81.5%) did not develop mortality. When the statistically significant results are evaluated according to multivariate analysis; Age, Crp, MASCC, acute renal failure, and hypotension were similar in both groups. On the other hand, when univariate statistically highly significant results are evaluated according to multivariate analysis; the Presence of urinary catheter, diagnosis of bacterial pneumonia, and ANS not increasing after 1 week were found to be statistically significant in the mortality group. \u0000Conclusion: The results of the study showed that in febrile neutropenic patients, mortality was increased by 6.7 times by a diagnosis of bacterial pneumonia, 245.6 times by the absence of ANS elevation, and 13.9 times by urinary catheterization.","PeriodicalId":210697,"journal":{"name":"DAHUDER Medical Journal","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122873298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Methamphetamine Addiction","authors":"Bilge İvecen, O. Gokdemir","doi":"10.56016/dahudermj.1184367","DOIUrl":"https://doi.org/10.56016/dahudermj.1184367","url":null,"abstract":"A person can develop addiction to many kinds of substances. Methamphetamine is the second most widely abused drug worldwide. Long-term methamphetamine usage may cause social, psychological, and physical problems. Long-term effects (such as weight loss, memory loss, tremors, convulsion, psychosis, paranoia, hallucinations, Parkinson's-like symptoms, and cardiovascular collapse) and short-term effects (such as euphoria, dilated pupils, insomnia, reduced appetite, increased blood pressure ) are listed and, brain damage and mental problems due to methamphetamine abuse are briefly mentioned in this text. The severity of withdrawal symptoms varies from person to person. Unfortunately, there is no exact cure for methamphetamine abuse. This is not a systematic review.","PeriodicalId":210697,"journal":{"name":"DAHUDER Medical Journal","volume":"43 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132208882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Human Metapneumovirus Pneumonia During The Sars Cov-2 Pandemic","authors":"Serap Cetiner, Özgür Okuturlar, Özlem Kaplan","doi":"10.56016/dahudermj.1167707","DOIUrl":"https://doi.org/10.56016/dahudermj.1167707","url":null,"abstract":"Human metapneumovirus (HMPV) is a virus from the paramyxovirus family identified in 2001. It is the second most common cause of lower respiratory tract infection in children after respiratory syncytial virus. In adults, it is mostly seen in the elderly population, immunosuppressive patients or those with a concomitant chronic disease. Human metapnemovirus can cause various clinical pictures ranging from a simple upper respiratory tract infection to bronchiolitis and asthma attack, from severe pneumonia to encephalitis and acute respiratory distress syndrome. In the case of viral infection in adults, especially during the Covid-19 pandemic, clinical and laboratory findings are similar, so it should be kept in mind in the differential diagnosis. This article is presented to draw attention to the inclusion of HMPV in the differential diagnosis of a 65-year-old female patient who applied to the practice with the complaints of high fever, cough, wheezing and headache during the Covid-19 pandemic. It has become important to detect the causative agent with multiple molecular tests and direct antigen tests in terms of differential diagnosis in respiratory tract infections, which are generally seen in adults during the pandemic. After the viral agent is determined with the diagnosis of the causative agent, the infection can be controlled more easily with the right treatment and the unnecessary use of antibiotics can be prevented.","PeriodicalId":210697,"journal":{"name":"DAHUDER Medical Journal","volume":"40 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131427279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Cardiac Risk Factors in Patients with Nephrotic Syndrome and Secondary Amyloidosis","authors":"Osman Cüre, T. Ayaz, K. Cengiz","doi":"10.56016/dahudermj.1108002","DOIUrl":"https://doi.org/10.56016/dahudermj.1108002","url":null,"abstract":"Proteinuria is an independent risk factor for cardiovascular diseases and for the increment of atherosclerotic mortality. Atherosclerotic risk factors are well known in the various types of nephrotic syndrome but there are only few studies comparing the same risk factors between the secondary amyloidosis and nephrotic syndrome patients those have exactly same 24- hour protein levels in the urine. According to theliterature, recent comparative studies have not shown the etiological differences of atherosclerotic risk factors in these two disease groups. The aim of this study was to investigate the risk factors caused byproteinuria on development of atherosclerosis and to determine the differences in these disease groups those were well- matched in age, gender, arterial blood pressure levels, glomerular filtration rate (GFR) and body mass index. These patients groups were chosen to have exactly the same 24- hour protein levels in urine. 29 patients with nephrotic syndrome, 30 patients with secondary amyloidosis and 30 people of control group were taken to the trial. C- reactive protein (CRP), fibrinogen, cholesterol, triglyceride, low density lipoprotein (LDL-C), high density lipoprotein (HDL-C), lipoprotein -a [Lp(a)], apo- lipoprotein Al (apo Al), apolipoprotein B (apo B), apo- lipoprotein E (apo E), GFR and 24- hour protein in urine were compared between the patients and control groups. \u0000In the patients groups; cholesterol, triglyceride, LDL-C, Lp(a), apo A, apo B, apo E and fibrinogen levels were \u0000 found much higher than the control group whereas HDL-C levels were lower (p","PeriodicalId":210697,"journal":{"name":"DAHUDER Medical Journal","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131220272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retrospective Evaluation of In-Hospital and Thirty-Month Mortality Parameters in Cases of Acute Coronary Syndrome","authors":"B. Alan, L. Kayikçioğlu, Irmak SAYIN ALAN","doi":"10.56016/dahudermj.1112297","DOIUrl":"https://doi.org/10.56016/dahudermj.1112297","url":null,"abstract":"Objectives: The aim of this study is to retrospectively assess, from the hospital records of patients, the clinical data of patients and the treatment strategies practiced on patients who were diagnosed as Acute Coronary Syndrome (ACS) and hospitalized and treated in the Hospital of Faculty of Medicine to research the effect of these data on occurrence of cardiovascular events and 30 months mortality. Methods: It is a retrospective screening study in which patients hospitalized with the diagnosis of ACS between June 2007 and December 2008 in the Hospital of Faculty of Medicine Cardiology Clinic are evaluated by using patient file information and electronic data recording system information, and by calling patients. In-hospital and long-term follow-up deaths were the endpoints of the study. Statistical analysis was performed using SPSS (Version 15.0). Results: 985 patients were included in the study who were diagnosed as ACS, hospitalized and treated in the hospital. The categorization of the patients subjected to the analysis (n:901) according to their diagnosis is as follows: 339 (38%) cases diagnosed as UAP, 206 (23%) cases diagnosed as NSTEMI, and 356 (39%) cases diagnosed as STEMI. 78,4 % of cases were male while 21,6 % were female. It was found that cases with hypertension, hyperlipidemia, obesity risk factor, and with a history of cardiovascular disease fall into the NSTEMI and UAP groups with a larger proportion. Among the groups, the UAP diagnosed cases have the largest and the STEMI diagnosed cases have the smallest ratio of using medicine groups such as beta blocker, calcium-canal blocker, ACE inhibitor, ARB, diuretic, statin, fibrate and nitrate before being hospitalized. In-hospital mortality was frequently encountered with a percentage of 7.6 % in STEMI cases, 2.4 % in NSTEMI cases, and 0.6 % in UAP cases. 30-months of follow-up data were obtained in all diagnosis groups for long-term mortality assessment. 70 (7.8 %) deaths were observed within the follow-up. According to diagnosis groups, death was observed in 22 (6.5 %) of UAP cases, 22 (10.7 %) of NSTEMI cases, and 26 (7.3 %) of STEMI cases. Correlation between long-term survival (30 months) and in-hospital statin usage and statin usage in discharge was not significant (p value respectively 0.1 and 0.16). Correlation between an approximate 30-months-survival and in-hospital ACE inhibitor/ARB inhibitor usage and ACE inhibitor/ARB inhibitor usage during discharge was significant (p = 0.007 and p = 0.004). It is also found that there was a significant correlation between survival in the same period of time and in-hospital beta blocker usage (p = 0.01). There was not a significant correlation between beta blocker usage during discharge and long-term survival (p = 0.779). Conclusion: Results of the unicentral retrospective scanning study which involves 901 ACS diagnosed patients prove to be similar to the ones obtained from GRACE and Euro Heart Survey prospective studies which we","PeriodicalId":210697,"journal":{"name":"DAHUDER Medical Journal","volume":"32 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114575711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does the frequency of diabetes increase in Covid-19 patients? cross-sectional study","authors":"Ihsan Solmaz, S. Araç","doi":"10.56016/dahudermj.1146367","DOIUrl":"https://doi.org/10.56016/dahudermj.1146367","url":null,"abstract":"Objective: The aim of this study was to investigate frequency of diabetes mellitus (DM) in patients diagnosed with Covid-19 and whether Covid-19 had effect on high HbA1c. \u0000Material-Methods: Data of DM patients with Covid-19 were analyzed cross-sectionally. In Covid-19, the effect of DM patient frequency and mortality was investigated. \u0000Results: 2057 patients diagnosed with Covid-19 were included in the study. Among these patients, total 192 patients (9.25%) were treated with the diagnosis of DM. 73 (41 males-32 females) were newly diagnosed with DM (38.02%). 119 patients (48 males and 71 females) were previously diagnosed with DM. Eight of DM patients died. Among all Covid-19 in patients followed up, 90 patients died. Mortality of DM patients was not statistically significant compared to mortality of all patients (p=1.000 x=0). Of the patients who were followed up with diagnosis of DM, whose HbA1c were observed in the last 3 months, 16 of 20 patients had increase in HbA1c, and 4 patients had decrease in HbA1c. The mean increase was 1.05. \u0000Conclusion: The frequency of new diagnosis DM in patients with Covid-19 was found to be quite high. There was increase in HbA1c in Covid-19 patients, and Covid-19 was thought to affect the pancreas.","PeriodicalId":210697,"journal":{"name":"DAHUDER Medical Journal","volume":"118 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133851639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of anti TNF alpha (certolizumab) treatment on insulin resistance, lipid parameters and cardiovascular risk in patients with axial spondyloarthritis (ankylosing spondylitis)","authors":"Hasan Göğebakan, G. Yıldırım Çetin","doi":"10.56016/dahudermj.1146178","DOIUrl":"https://doi.org/10.56016/dahudermj.1146178","url":null,"abstract":"Objectives: To evaluate the effects of certolizumab treatment on insulin resistance (IR), lipid parameters, and cardiovascular (CV) risk in patients with ankylosing spondylitis (AS). \u0000Methods: This prospective study included 80 consecutive patients with AS (52 males, 28 females) and 74 control subjects (48 males, 26 feemales). The AS patients and control group were compared in respect of basal values. All AS patients with active disease were treated with certolizumab. Biochemical profiles were obtained before and after 24 weeks of certolizumab treatment. Homeostatic model assessment-insulin resistance (HOMA-IR) was used to measure IR and the quantitative insulin sensitivity control index (QUICKI) was used to measure insulin sensitivity. The Framingham equation was used to evaluate CV risk factors. \u0000Results: A statistically significant increase was determined in total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and triglyceride (TG) values after 24 weeks of certolizumab treatment. No statistically significant change was determined in the plasma atherogenic index (PAI) and low-density lipoprotein cholesterol (LDL-C) values. A statistically significant decrease was determined in HOMA-IR and an increase in QUICKI. When the Framingham risk scoring was compared with the baseline values, a statistically significant decrease in risk was found at week 24. \u0000Conclusions: Certolizumab therapy was associated with a significant increase in HDL-C, TC, and TG levels without any significant change in PAI and LDL-C, and was determined to increase insulin sensitivity and lower insulin resistance. There was also a significant reduction in SBP and 10-year Framingham risk scores at 24 weeks after the start of certolizumab therapy.","PeriodicalId":210697,"journal":{"name":"DAHUDER Medical Journal","volume":"771 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127982554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Anemia Frequency and Types in Patients with Subclinical and Clinical Hypothyroidism in the Endemic Goiter Region","authors":"Kadir Ilkkilic, T. Ayaz, E. Algün","doi":"10.56016/dahudermj.1108040","DOIUrl":"https://doi.org/10.56016/dahudermj.1108040","url":null,"abstract":"ABSTRACT \u0000Objective: Hypothyroidism is a disease that occurs as a result of thyroid hormone deficiency or rarely, due to ineffectiveness at the tissue level. While the prevalence of clinical hypothyroidism is reported to be 2-5% worldwide, of subclinical hypothyroidism it is 4-8.5%, with the prevalence of subclinical hypothyroidism in women over 60 years of age being 14-20%. Hypothyroidism affects many organs and systems in the body, one of which is the hematopoietic system. Thyroid hormone deficiency plays a role in the development of microcytic, normocytic and macrocytic anemia. The frequency of anemia in patients with hypothyroidism varies between 20-60%. In this study, our aim was to determine the regional prevalence of subclinical and clinical hypothyroidism in adult patients in our region and to evaluate the frequency and types of anemia in patients with hypothyroidism. \u0000 \u0000Method and Material: This study was prospectively conducted between 01.12.2012 and 01.05.2013 at the outpatient clinic of Recep Tayyip Erdogan University Faculty of Medicine Endocrinology. Included in the study were 96 patients who had subclinical hypothyroidism, 30 patients who had clinical hypothyroidism, and 100 healthy controls. Normal fT4 and fT3, high TSH values were used for the diagnosis of subclinical hypothyroidism, and low fT4 and/or fT3, high TSH values were used for the diagnosis of clinical hypothyroidism. The diagnosis of anemia was based on subclinical hypothyroidism, clinical hypothyroidism, and control group Hb value","PeriodicalId":210697,"journal":{"name":"DAHUDER Medical Journal","volume":"125 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126757653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Approach to the metastatic bone lesions; tumor investigation in a patient without cancer","authors":"S. Uyar, F. Bostan","doi":"10.56016/dahudermj.1097922","DOIUrl":"https://doi.org/10.56016/dahudermj.1097922","url":null,"abstract":"","PeriodicalId":210697,"journal":{"name":"DAHUDER Medical Journal","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127989860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}